

THE FIRST AND ONLY IV IBUPROFEN FOR PAIN AND FEVER


**MORE PAIN CONTROL  
WITH LESS NARCOTIC<sup>1</sup>**



**SIGNIFICANT REDUCTION IN PAIN INTENSITY SCORES<sup>2</sup>**

CALDOLOR is indicated in adults for the management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, and reduction of fever.

**26% mean reduction in pain  
with movement\* ( $p < 0.001$ )**



**SIGNIFICANT REDUCTION IN NARCOTIC USE<sup>2</sup>**

**31% reduction in mean narcotic use ( $p < 0.001$ )**

**32% reduction in pain at rest ( $p < 0.001$ )**

Hospitalized patients undergoing hip or knee replacement, reconstruction or arthroplasty surgery received 800 mg CALDOLOR or placebo every 6 hours (started at induction of anesthesia) and morphine on an as needed basis.<sup>2</sup>

**FOR CLINICAL INFORMATION, VISIT [WWW.CALDOLOR.COM](http://WWW.CALDOLOR.COM).**

**WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS**

Cardiovascular Risk

- Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use
- CALDOLOR is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery

Gastrointestinal Risk

- NSAIDs increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Events can occur at any time without warning symptoms. Elderly patients are at greater risk

#### IMPORTANT SAFETY INFORMATION

CALDOLOR should be used with caution in patients with congestive heart failure, kidney impairment, at risk of blood clots, and in those who have a history of ulcers or gastrointestinal bleeding. When used in such patients, attention to using the lowest effective dose for the shortest time period is important to reduce the risk of serious adverse events. Ibuprofen has been associated with high blood pressure, serious skin reactions, and serious allergic reactions.

The most common adverse events reported in the controlled clinical trials were nausea, flatulence, vomiting, and headache.

Please see enclosed full Prescribing Information, including Boxed Warning

**Reference:** 1. Caldolor [prescribing information](#). Nashville, TN: Cumberland Pharmaceuticals Inc; 2009.  
2. Singla N, et al. A Multi-Center, Randomized, Double-Blind Placebo-Controlled Trial of Intravenous-Ibuprofen (IV-Ibuprofen) for Treatment of Pain in Post-Operative Orthopedic Adult Patients. *Pain Med* 2010;11:1284-1293.

CALDOLOR is a registered trademark of [Cumberland Pharmaceuticals Inc](#)



2525 West End Avenue, Suite 950  
Nashville, Tennessee 37203  
WWW1471110

**CALDOLOR<sup>®</sup>**  
(ibuprofen) Injection